FR 192752
Latest Information Update: 05 Jun 2001
Price :
$50 *
At a glance
- Originator Fujisawa
- Class Antibacterials; Cephalosporins; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 05 Jun 2001 No-Development-Reported for Bacterial infections in Japan (Unknown route)
- 27 Aug 1997 New profile
- 27 Aug 1997 Preclinical development for Bacterial infections in Japan (Unknown route)